       Document 0869
 DOCN  M9460869
 TI    Long-term effects of early nutritional support with new enterotropic
       peptide-based formula vs. standard enteral formula in HIV-infected
       patients: randomized prospective trial [see comments]
 DT    9404
 AU    Chlebowski RT; Beall G; Grosvenor M; Lillington L; Weintraub N; Ambler
       C; Richards EW; Abbruzzese BC; McCamish MA; Cope FO; UCLA-Harbor Medical
       Center, Torrance.
 SO    Nutrition. 1993 Nov-Dec;9(6):507-12. Unique Identifier : AIDSLINE
       MED/94154398
 CM    Comment in: Nutrition 1993 Nov-Dec;9(6):554-6
 AB    Despite association with adverse clinical outcome, human
       immunodeficiency virus (HIV)-associated malnutrition has been relatively
       refractory to conventional nutrition management. Consequently, a
       prospective randomized trial was conducted to evaluate a new
       peptide-based enteral formula (NEF) in contrast to a standard enteral
       formula (SEF) in patients with HIV infection. Eighty early-stage largely
       asymptomatic patients were randomized into a dietary regimen
       supplemented with either a ready-to-feed NEF (18.7% protein, 65.5%
       carbohydrate, 15.8% fat; 1.28 kcal/ml) or SEF (14% protein, 55%
       carbohydrate, 31% fat; 1.06 kcal/ml). Patients received 2-3 8-oz cans of
       the NEF or SEF supplement per day for 6 mo. Parameters evaluated at 0
       (baseline), 3, and 6 mo included adherence, weight change,
       anthropometric measurements, serum biochemical indices, gastrointestinal
       symptoms, physical performance, and intercurrent health events
       (including hospitalizations). For the 56 evaluable patients, those
       supplemented with NEF maintained their body weight significantly (p =
       0.04) better, had significantly (p = 0.03) more stable triceps skin-fold
       measurements, and had significantly (p = 0.04) lower blood urea nitrogen
       than patients consuming the SEF supplement. Consumption of the NEF
       supplement was also associated with significantly reduced
       hospitalizations during the 3- to 6-mo evaluation period (p = 0.02). The
       NEF supplement was well tolerated and did not result in untoward
       clinical effects. These data suggest that supplemental use of an NEF
       provides superior nutritional management compared with an SEF for
       patients with early-stage HIV infection.
 DE    Adolescence  Adult  Analysis of Variance  Blood Urea Nitrogen  Body
       Weight  Caloric Intake  Comparative Study  Creatinine/BLOOD  Dietary
       Proteins/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  Enteral Nutrition
       Female  Follow-Up Studies  *Food, Formulated  Hospitalization  Human
       HIV Infections/COMPLICATIONS/*DIET THERAPY  Male  Middle Age  Patient
       Compliance  Prospective Studies  Protein-Energy
       Malnutrition/ETIOLOGY/*PREVENTION & CONTROL  Serum Albumin/ANALYSIS
       Skinfold Thickness  CLINICAL TRIAL  JOURNAL ARTICLE  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

